Valuation: IN8bio, Inc.

Market Cap 9.64M 8.34M 7.78M 7.14M 13.43M 917M 13.64M 91.33M 35.85M 460M 36.19M 35.39M 1.52B P/E 2026 *
-0.66x
P/E 2027 * -0.99x
Enterprise Value 9.64M 8.34M 7.78M 7.14M 13.43M 917M 13.64M 91.33M 35.85M 460M 36.19M 35.39M 1.52B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
86.51%
Yield 2026 *
-
Yield 2027 * -
1 day+0.90%
1 week-5.45%
Current month-5.45%
1 month-29.09%
3 months-38.06%
6 months-50.82%
Current year-58.18%
1 week 0.9
Extreme 0.9
1.08
1 month 0.9
Extreme 0.9
1.46
Current year 0.9
Extreme 0.9
2.73
1 year 0.9
Extreme 0.9
2.73
3 years 0.9
Extreme 0.9
74.4
5 years 0.9
Extreme 0.9
309.57
10 years 0.9
Extreme 0.9
309.57
Manager TitleAgeSince
Chief Executive Officer 50 2015-10-31
Chief Tech/Sci/R&D Officer 72 2018-10-31
Director of Finance/CFO 43 2021-02-07
Director TitleAgeSince
Director/Board Member 50 2015-10-31
Director/Board Member 68 2019-06-30
Director/Board Member 64 2021-08-03
Date Insider Type Main position Quantity % Market Cap.
5/9/26 Free

Director

22,000 0.2234%
2/4/26 Free

Founder

72,000 0.7372%
2/4/26 Free

Chairperson

80,000 0.8192%
Change 5-day change 1-year change 3-year change Capi.($)
+0.90%-5.45%-57.64%-97.21% 9.64M
+8.49%+20.55%+70.77%+110.32% 68.12B
+1.25%+2.44%+34.27%+70.43% 55.18B
-1.09%+32.96%+19.67%+494.56% 28.63B
+10.83%+18.38%+56.20%+6.03% 23.99B
+2.72%+3.41%-16.11%-7.96% 23.53B
+6.50%+7.56%+44.65%-21.73% 18.45B
+6.20%+11.51%+33.87%+693.38% 16.44B
-3.88%+16.98%+199.30%+359.77% 15.83B
+3.58%+1.96%+43.35%+163.76% 13.4B
Average +3.55%+9.97%+42.83%+177.14% 26.36B
Weighted average by Cap. +4.36%+13.09%+50.69%+168.46%

Financials

2026 *2027 *
Net sales - -
Net income -21.15M -18.29M -17.08M -15.67M -29.47M -2.01B -29.94M -200M -78.66M -1.01B -79.41M -77.67M -3.33B -23.89M -20.67M -19.3M -17.71M -33.3M -2.27B -33.83M -226M -88.88M -1.14B -89.73M -87.76M -3.77B
Net Debt - -
Logo IN8bio, Inc.
IN8bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Employees
-
Date Price Change Volume
26-08-07 US$0.9786 +0.90% 36,582
26-08-06 US$0.9699 -1.91% 76,865
26-08-05 US$0.9888 +2.99% 39,883
26-08-04 US$0.9601 +0.01% 37,736
26-08-03 US$0.9600 -7.25% 152,091
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9786USD
Average target price
6.250USD
Spread / Average Target
+538.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INAB Stock